Marex Group plc Announces Pricing of Initial Public Offering
April 24 2024 - 8:33PM
Marex Group plc (“Marex”), the diversified global financial
services platform, today announces the pricing of its initial
public offering (the “IPO”), at $19.00 per share. A total of
15,384,615 ordinary shares are being offered, of which 3,846,153
shares are being offered by Marex and 11,538,462 shares are being
offered by certain selling shareholders (the “Selling
Shareholders”). Marex will not receive any proceeds from any sale
of shares by the Selling Shareholders. The ordinary shares are
expected to begin trading on the Nasdaq Global Select Market on
April 25, 2024, under the ticker symbol “MRX.” The offering is
expected to close on April 29, 2024, subject to customary closing
conditions.
In connection with the offering, the Selling
Shareholders have granted the underwriters a 30-day option to
purchase up to an additional 2,307,692 ordinary shares to cover
over-allotments.
Barclays, Goldman Sachs & Co. LLC, Jefferies
and Keefe, Bruyette & Woods, a Stifel Company, are acting as
joint lead book-running managers and as representatives of the
underwriters for the proposed offering. Citigroup, UBS Investment
Bank, Piper Sandler and HSBC are acting as bookrunners for the
proposed offering. Drexel Hamilton and Loop Capital Markets are
acting as co-managers for the proposed offering.
The proposed offering is being made only by
means of a prospectus. Copies of the prospectus relating to the
proposed offering may be obtained from:
- Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone
at 1-888-603-5847, or by email at
barclaysprospectus@broadridge.com;
- Goldman Sachs & Co. LLC, Attention: Prospectus Department,
200 West Street, New York, New York 10282, via telephone:
1-866-471-2526, or via email: prospectus-ny@ny.email.gs.com;
- Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, New York, NY 10022, by phone at
(877) 821-7388, or by email at Prospectus_Department@Jefferies.com;
or
- Keefe, Bruyette & Woods Inc., 787 Seventh Avenue, Fourth
Floor, New York, NY 10019, attention: Equity Capital Markets, or by
calling toll free at (800) 966-1559 or emailing
USCapitalMarkets@kbw.com.
A registration statement relating to these
securities has been filed with, and was declared effective by, the
U.S. Securities and Exchange Commission. This press release does
not constitute an offer to sell or the solicitation of an offer to
buy any securities, and shall not constitute an offer, solicitation
or sale in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under
the securities laws of that jurisdiction.
Enquiries please contact:
Nicola Ratchford / Robert CoatesMarex +44 (0) 7786548889 / +44
(0) 7880486329 | nratchford@marex.com / RCoates@marex.com
FTI Consulting US / UK+1 (919) 609-9423 / +44 (0) 7776 111 222 |
marex@fticonsulting.com
Marex (NASDAQ:MRX)
Historical Stock Chart
From Jan 2025 to Feb 2025
Marex (NASDAQ:MRX)
Historical Stock Chart
From Feb 2024 to Feb 2025